Literature DB >> 2011399

Retinoblastoma gene deletions in human glioblastomas.

D J Venter1, K L Bevan, R L Ludwig, T E Riley, P S Jat, D G Thomas, M D Noble.   

Abstract

The retinoblastoma susceptibility gene, RB, is the best characterised of the tumour suppressor genes, or 'anti-oncogenes'. Abnormal function of the RB protein is thought to result in loss of an inhibitory effect on cell growth, and thus contribute towards the development of certain human cancers. One group of human cancers of particular interest in relationship to retinoblastoma gene function are the gliomas, which are central nervous system tumours thought to originate from the neuroectoderm, the embryological tissue which also gives rise to retinoblastomas. We have therefore examined a group of benign and malignant gliomas for evidence of structural alterations of the RB gene. Four out of nine (44%) glioblastomas, the most malignant gliomas, showed loss of heterozygosity of a locus within this gene. In addition, one of these hemizygous tumours showed deletion of part of the RB protein-coding region, and this abnormality was also present in cells cultured from the tumour. These findings suggest that RB gene abnormalities may contribute to the development of glioblastomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2011399

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

2.  P16 deletion and mutation analysis in human brain tumors.

Authors:  F G Barker; P Chen; F Furman; K D Aldape; M S Edwards; M A Israel
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

3.  Perturbation of the p53 response by human papillomavirus type 16 E7.

Authors:  E S Hickman; S Bates; K H Vousden
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

4.  Rb1/105 gene alterations and head and neck carcinogenesis.

Authors:  Maimoona Sabir; Ruqia Mehmood Baig; Ishrat Mahjabeen; Muhammad Saeed; Faraz Arshad Malik; Mahmood Akhtar Kayani
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

5.  Establishment of two glioma cell lines from two surgical specimens obtained at different times from the same individual.

Authors:  K Onda; S Nagai; R Tanaka; K Morii; J I Yoshimura; I Tsumanuma; T Kumanishi
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 6.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

7.  Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas.

Authors:  C E Jones; M B Davis; J L Darling; J F Geddes; D G Thomas; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

Review 8.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

9.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 10.  Genetics of primary brain tumors: a review.

Authors:  M Bondy; J Wiencke; M Wrensch; A P Kyritsis
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.